ORPHA:370396
Small cell carcinoma of the ovary
Also known as: SCCO · Small cell ovarian carcinoma
Publications
915
Trials
2
Interventional, condition-specific
Researchers
1,191
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Small cell carcinoma of the ovary is a rare, highly aggressive, poorly differentiated ovarian neoplasm, often associated with paraneoplastic hypercalcemia. It is usually diagnosed in childhood or young adulthood at an advanced stage and presents with abdominal or pelvic mass or, rarely, symptoms related to hypercalcemia. Occasional familial cases have been reported.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0003795
- UMLS:C2212006
- NCIT:C27390
Additional Mondo synonyms (8)
ovarian small cell NEC · ovarian small cell cancer · ovarian small cell carcinoma · ovarian small cell neuroendocrine carcinoma · ovary small cell carcinoma · small cell carcinoma of ovary · small cell carcinoma of the ovary · small cell ovarian carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
915 matched papers (652 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
2
Drugs / clinical candidates · MONDO_0003795
- PEMBROLIZUMAB·phase 1
- SECLIDEMSTAT·phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
915
915 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
915 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
652 in the last 10 years · low confidence
Phrase hits: 915 · MeSH hits: 0
Who's working on it?
1,191
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Foulkes WD13 papers · 2026
Department of Human Genetics, McGill University, Montreal, QC, Canada.
Papers in Europe PMC - 02Wang Y8 papers · 2026
Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Institute, Vancouver, Canada.
Papers in Europe PMC - 03Kang Y7 papers · 2026
Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.
Papers in Europe PMC - 04McCluggage WG7 papers · 2026
Department of Pathology, Belfast Health and Social Care Trust, Royal Group of Hospitals Trust, Royal Group of Hospitals, Belfast, UK.
Papers in Europe PMC - 05Zhang Y6 papers · 2026
Johns Hopkins University School of Medicine, Baltimore, MD.
Papers in Europe PMC - 06Gao Y5 papers · 2025
Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.
Papers in Europe PMC - 07Lang JD5 papers · 2025
Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, United States.
Papers in Europe PMC - 08Witkowski L5 papers · 2026
Department of Human Genetics, McGill University, Montreal, QC, Canada.
Papers in Europe PMC - 09Zheng K5 papers · 2025
Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.
Papers in Europe PMC - 10Chen X4 papers · 2026
Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Jiangsu Key Laboratory of innovative Cancer Diagnosis & Therapeutics, 42# Baiziting street, Nanjing, Jiangsu, 210009, China. cxxxxcyd@gmail.com.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 321 trials are registered for small cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
low confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04602377·RECRUITING·Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Not reviewed·Conditions: Small Cell Ovarian Carcinoma·Matched via name phrase
Broader category: small cell carcinoma
321
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06982222·NOT YET RECRUITING·Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
Not reviewed·Conditions: Anatomic Stage IV Breast Cancer AJCC v8 · Metastatic Breast Carcinoma · Metastatic Lung Non-Small Cell Carcinoma · Metastatic Malignant Neoplasm in the Bone·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT06816394·NOT YET RECRUITING·Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)
Not reviewed·Conditions: Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma·Matched via name phrase
- NCT05173246·RECRUITING·JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma
Not reviewed·Conditions: Esophageal Small Cell Carcinoma·Matched via name phrase
- NCT06057766·RECRUITING·Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer
Not reviewed·Conditions: Non Small Cell Lung Cancer · Non-small Cell Carcinoma·Matched via name phrase
- NCT04696575·RECRUITING·Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Not reviewed·Conditions: Extensive Stage Lung Small Cell Carcinoma·Matched via name phrase
- NCT07144280·RECRUITING·A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Not reviewed·Conditions: Non-small Cell Carcinoma · Non-Small Cell Lung Cancer Metastatic · Non-Small Cell Lung Carcinoma·Matched via name phrase
- NCT07293247·RECRUITING·A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Not reviewed·Conditions: Lung Non-Small Cell Carcinoma·Matched via name phrase
- NCT06014827·RECRUITING·Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
Not reviewed·Conditions: Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8·Matched via name phrase
- NCT06616584·RECRUITING·Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Not reviewed·Conditions: Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8·Matched via name phrase
- NCT06500455·RECRUITING·Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Not reviewed·Conditions: Anatomic Stage IV Breast Cancer AJCC v8 · Metastatic Breast Carcinoma · Metastatic Digestive System Carcinoma · Metastatic Lung Non-Small Cell Carcinoma·Matched via name phrase
- NCT06464068·RECRUITING·AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
Not reviewed·Conditions: Extrapulmonary Small Cell Carcinoma·Matched via name phrase
- NCT07216404·RECRUITING·Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
Not reviewed·Conditions: Lung Non-Small Cell Carcinoma · Unipolar Depression·Matched via name phrase
- NCT05502523·RECRUITING·The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
Not reviewed·Conditions: Lung Non-Small Cell Carcinoma · Stage I Lung Cancer AJCC v8 · Stage II Lung Cancer AJCC v8 · Stage III Lung Cancer AJCC v8·Matched via name phrase
- NCT06228066·RECRUITING·Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · High Grade Neuroendocrine Tumors of the Urinary Tract·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT01970696·RECRUITING·International Ovarian & Testicular Stromal Tumor Registry
Not reviewed·Conditions: Ovarian Sex-cord Stromal Tumor · Testicular Stromal Tumors · Ovarian Small Cell Carcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 17 · after dedupe 17 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 17 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (17)
- ctis·2024-515310-40-01·Authorised, ongoing·Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ovarian carcinoma of hypercalcemic type
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15842444·Recruiting·Assessing the safety of atezolizumab being directly administered to the bladder in bladder cancer patients undergoing radical cystectomy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11595117·No longer recruiting·A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN58060459·No longer recruiting·A study of cibisatamab in participants with locally advanced and/or metastatic carcinoembryonic antigen positive solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62918594·No longer recruiting·A Phase I/IIa trial of HMBD-001 in advanced HER3-positive solid tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14753723·Recruiting·A study to test the safety, tolerability and effect of ZI-MA4-1 for patients with locally advanced or metastatic solid malignancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN84044406·No longer recruiting·A Phase I trial of LY3143921 hydrate in solid tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78284158·No longer recruiting·Heated intraperitoneal chemotherapy for the treatment of primary ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26628699·Recruiting·A Phase I/II trial of UCB4594 in participants with advanced cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13282459·Recruiting·SOPRANO - Stereotactic radiotherapy alone or stereotactic radiotherapy follow by niraparib treatment for ovarian cancer with progressive disease in three or less lesions, or recurrence of 3 or less metastatic lesions that had previously achieved complete response.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12633596·No longer recruiting·A study to test mirvetuximab soravtansine in women with platinum sensitive, advanced epithelial ovarian, primary peritoneal, or fallopian tube cancers.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12839469·No longer recruiting·A study to characterize the impact of dietary modification on inavolisib associated hyperglycaemia and to assess the CYP3A4 induction potential of inavolisib using midazolam as a probe substrate in participants with incurable metastatic solid tumours previously treated with multiple (≥2) lines of therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16171129·No longer recruiting·A randomised Phase II trial to assess whether niraparib is beneficial in patients with mesothelioma that has progressed and been previously treated when compared to the standard of care treatment, termed active symptom control
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN35774409·No longer recruiting·A study to evaluate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of RO7009789 (selicrelumab) in combination with vanucizumab or bevacizumab in patients with metastatic solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12196200·No longer recruiting·Can we use estrogen-containing therapy to improve pain in women after menopause with hand osteoarthritis? (HOPE-e study)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11233255·No longer recruiting·BUTEO: a clinical trial of BTT1023 in patients with primary sclerosing cholangitis (PSC)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN32770468·No longer recruiting·Weekly administration of oral docetaxel in combination with ritonavir for the treatment of a variety of tumour types
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Small cell carcinoma of the ovary — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Small cell carcinoma of the ovary" OR "Small cell carcinoma of ovary" OR "Small cell ovarian carcinoma" OR "ovarian small cell NEC" OR "ovarian small cell cancer" OR "ovarian small cell carcinoma" OR "ovarian small cell neuroendocrine carcinoma" OR "ovary small cell carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Small cell carcinoma of the ovary" OR "Small cell carcinoma of ovary" OR "Small cell ovarian carcinoma" OR "ovarian small cell NEC" OR "ovarian small cell cancer" OR "ovarian small cell carcinoma" OR "ovarian small cell neuroendocrine carcinoma" OR "ovary small cell carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 1 observational · 1 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"small cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: SCCO
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (915) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T14:57:21.685Z
